Results 1 to 10 of about 2,999 (191)

LDL-Apheresis: Technical and Clinical Aspects [PDF]

The Scientific World Journal, 2012
The prognosis of patients suffering from severe hyperlipidemia, sometimes combined with elevated lipoprotein (a) levels, and coronary heart disease refractory to diet and lipid-lowering drugs is poor. For such patients, regular treatment with low-density
Rolf Bambauer, Carolin Bambauer, Boris Lehmann, Reinhard Latza, Ralf Schiel   +4 more
doaj   +4 more sources

HELP LDL apheresis reduces plasma pentraxin 3 in familial hypercholesterolemia. [PDF]

PLoS ONE, 2014
BACKGROUND:Pentraxin 3 (PTX3), a key component of the humoral arm of innate immunity, is secreted by vascular cells in response to injury, possibly aiming at tuning arterial activation associated with vascular damage.
Michela Zanetti, Mariagrazia Zenti, Rocco Barazzoni, Federica Zardi, Annamaria Semolic, Michele Giuseppe Messa, Filippo Mearelli, Gianpaolo Russi, Maurizio Fonda, Luca Scarano, Enzo Bonora, Luigi Cattin   +11 more
doaj   +2 more sources

LDL apheresis as an alternate method for plasma LPS purification in healthy volunteers and dyslipidemic and septic patients [PDF]

Journal of Lipid Research, 2020
Lipopolysaccharide (LPS) is a key player for innate immunity activation. It is therefore a prime target for sepsis treatment, as antibiotics are not sufficient to improve outcome during septic shock.
Auguste Dargent, Jean-Paul Pais de Barros, Samir Saheb, Randa Bittar, Wilfried Le Goff, Alain Carrié, Thomas Gautier, Isabelle Fournel, Anne Laure Rerole, Hélène Choubley, David Masson, Laurent Lagrost, Jean-Pierre Quenot   +12 more
doaj   +2 more sources

Combined Treatment With Lipoprotein Apheresis and Hemodialysis in Patients With Severe Cardiovascular Disease, High Lipoprotein(a) and End Stage Renal Disease. [PDF]

J Clin Apher
ABSTRACT Elevated Lipoprotein(a) (Lp(a)) is a known independent cardiovascular risk factor. Lp(a) Lipoprotein Apheresis (LA) substantially reduces the number of cardiovascular events. The effect of LA treatment in hemodialysis (HD) patients remains unknown. Retrospective analysis of nine patients undergoing LA and HD.
Röseler T, Kayser D, Schlieper G, Bernhardt WM.   +3 more
europepmc   +2 more sources

Influence of LDL apheresis on LDL subtypes in patients with coronary heart disease and severe hyperlipoproteinemia [PDF]

Journal of Lipid Research, 2000
Epidemiologic studies and in vitro experiments indicate that low density lipoprotein (LDL) subtypes differ concerning their atherogenic potential. Small, dense LDL are more atherogenic than large, buoyant LDL.
B.M. Schamberger, H.C. Geiss, M.M. Ritter, P. Schwandt, K.G. Parhofer   +4 more
doaj   +2 more sources

Rheocarna Effectively Treats Oral Medicinal Therapy-Resistant Cutaneous Symptoms and Renal Failure Induced by Cholesterol Crystal Embolism. [PDF]

Clin Case Rep
ABSTRACT An 80‐year‐old man presented to our hospital with worsening renal function and ambulation difficulties due to lower extremity symptoms that included livedo reticularis, gangrene, cyanosis, and ulcers in his legs. The patient was diagnosed with a cholesterol crystal embolism.
Satake A, Tokuda T, Ohashi H, Nakano Y, Kodama A, Amano T.   +5 more
europepmc   +2 more sources

The potential of heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.)-apheresis for patients with severe acute or chronic COVID-19 [PDF]

Frontiers in Cardiovascular Medicine, 2022
Patients with long COVID and acute COVID should benefit from treatment with H.E.L.P. apheresis, which is in clinical use for 37 years. COVID-19 can cause a severe acute multi-organ illness and, subsequently, in many patients the chronic illness long ...
Beate Roxane Jaeger, Hayley Emma Arron, Wiltrud M. Kalka-Moll, Dietrich Seidel   +3 more
doaj   +2 more sources

Long-Term LDL-Apheresis Treatment and Dynamics of Circulating miRNAs in Patients with Severe Familial Hypercholesterolemia. [PDF]

Genes (Basel), 2023
Dlouha D, Blaha M, Huckova P, Lanska V, Hubacek JA, Blaha V.   +5 more
europepmc   +3 more sources

Impact of LDL apheresis on atheroprotective reverse cholesterol transport pathway in familial hypercholesterolemia [PDF]

Journal of Lipid Research, 2012
In familial hypercholesterolemia (FH), low HDL cholesterol (HDL-C) levels are associated with functional alterations of HDL particles that reduce their capacity to mediate the reverse cholesterol transport (RCT) pathway.
Alexina Orsoni, Elise F. Villard, Eric Bruckert, Paul Robillard, Alain Carrie, Dominique Bonnefont-Rousselot, M. John Chapman, Geesje M. Dallinga-Thie, Wilfried Le Goff, Maryse Guerin   +9 more
doaj   +2 more sources

Hypercholesterolemia and inflammation-Cooperative cardiovascular risk factors. [PDF]

Eur J Clin Invest
Abstract Background Maintaining low concentrations of plasma low‐density lipoprotein cholesterol (LDLc) over time decreases the number of LDL particles trapped within the artery wall, slows the progression of atherosclerosis and delays the age at which mature atherosclerotic plaques develop.
Gallo A, Le Goff W, Santos RD, Fichtner I, Carugo S, Corsini A, Sirtori C, Ruscica M.   +7 more
europepmc   +2 more sources